NASDAQ:EDGE - Edge Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$7.20Today's Range$6.90 - $7.5852-Week Range$0.28 - $17.38Volume156,893 shsAverage Volume373,201 shsMarket Capitalization$226.87 millionP/E RatioN/ADividend YieldN/ABeta3.65 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. Receive EDGE News and Ratings via Email Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDGE Previous Symbol CUSIPN/A CIK1472091 Webhttp://www.edgetherapeutics.com/ Phone800-208-3343Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-40,860,000.00 Net MarginsN/A Return on Equity-81.29% Return on Assets-56.92%Miscellaneous EmployeesN/A Outstanding Shares31,510,000Market Cap$226.87 million Next Earnings DateN/A OptionableOptionable Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions What is Edge Therapeutics' stock symbol? Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE." How were Edge Therapeutics' earnings last quarter? Edge Therapeutics Inc (NASDAQ:EDGE) posted its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.16. View Edge Therapeutics' Earnings History. Has Edge Therapeutics been receiving favorable news coverage? Media coverage about EDGE stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edge Therapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Edge Therapeutics' key competitors? Some companies that are related to Edge Therapeutics include Myovant Sciences (MYOV), Kiniksa Pharmaceuticals (KNSA), Rocket Pharmaceuticals (RCKT), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), CymaBay Therapeutics (CBAY), Wave Life Sciences (WVE), ANI Pharmaceuticals (ANIP), Mallinckrodt (MNK), Dicerna Pharmaceuticals (DRNA), TherapeuticsMD (TXMD), Axsome Therapeutics (AXSM), ArQule (ARQL), Eagle Pharmaceuticals (EGRX) and CannTrust (CNTTF). What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Synergy Pharmaceuticals (SGYP), McEwen Mining (MUX), Amicus Therapeutics (FOLD), BIOLINERX LTD/S (BLRX), Cerecor (CERC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Arena Pharmaceuticals (ARNA) and Fate Therapeutics (FATE). Who are Edge Therapeutics' key executives? Edge Therapeutics' management team includes the folowing people: Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 54)Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 57)Mr. Andrew Saik, Chief Financial Officer (Age 50)Mr. W. Bradford Middlekauff, Sr. VP, Gen. Counsel & Sec. (Age 57)Mr. William Shatynski, Sr. Director of Financial Reporting & Controller How do I buy shares of Edge Therapeutics? Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How big of a company is Edge Therapeutics? Edge Therapeutics has a market capitalization of $0.00. What is Edge Therapeutics' official website? The official website for Edge Therapeutics is http://www.edgetherapeutics.com/. How can I contact Edge Therapeutics? Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected] MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 142 (Vote Outperform)Underperform Votes: 153 (Vote Underperform)Total Votes: 295MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Asset Allocation Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.